The expression of GATA6 has been proposed as a surrogate biomarker for the differentiation between basal-like and classic subtype, based on the observation that basal-like tumours have significantly lower levels of GATA6. 57,69,70 However, whether GATA6-low can be used as a predictive biomarker of therapeutic response needs further investigation.57 Here, GATA6 is linked to neoplasm.